What is Global Platinum based Cancer Drug Market?
The Global Platinum-based Cancer Drug Market is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. This market involves the use of platinum compounds, such as cisplatin, carboplatin, and oxaliplatin, as chemotherapy drugs in cancer treatments. These drugs are known to slow or stop cancer cells from growing and dividing. The platinum atom in these drugs binds to the DNA in cancer cells, causing damage and preventing the cells from dividing further. The global market for these drugs is driven by the increasing prevalence of cancer worldwide and the proven effectiveness of platinum-based drugs in treating various types of cancer. However, the market is also faced with challenges such as side effects associated with these drugs and the development of drug resistance by cancer cells.
Cisplatin, Oxaliplatin, Carboplatin, Others in the Global Platinum based Cancer Drug Market:
Cisplatin, Oxaliplatin, and Carboplatin are the primary platinum-based drugs used in the treatment of cancer. Cisplatin was the first platinum-based cancer drug to be developed and is still widely used today. It is particularly effective in treating testicular and ovarian cancers. Oxaliplatin and Carboplatin are newer drugs that have been developed to overcome some of the side effects associated with Cisplatin. Oxaliplatin is commonly used in the treatment of colorectal cancer, while Carboplatin is used in the treatment of lung cancer and ovarian cancer. However, there are other platinum-based drugs in the market, but their usage is not as widespread.
Colorectal Cancer, Ovarian Cancer, Lung Cancer, Others in the Global Platinum based Cancer Drug Market:
The Global Platinum-based Cancer Drug Market finds its applications in various areas of cancer treatment. The most common use of these drugs is in the treatment of colorectal cancer, which accounts for about 62% of the total market. These drugs are also used in the treatment of ovarian and lung cancers. However, the effectiveness of these drugs varies depending on the type of cancer and the stage at which it is diagnosed. For instance, platinum-based drugs are more effective in treating early-stage cancers compared to advanced-stage cancers.
Global Platinum based Cancer Drug Market Outlook:
The global Platinum-based Cancer Drug Market was valued at US$ 1541.9 million in 2022 and is projected to reach US$ 1862.2 million by 2029, growing at a CAGR of 2.7% during the forecast period 2023-2029. Oxaliplatin accounts for about 71% of the market. The largest market for platinum-based cancer drugs is Asia-Pacific, with a sales market share of nearly 53%. The leading players in the industry include Sanofi, Hengrui Medicine, ASK Pharma, Yi Bai Pharmaceutical, Qilu Pharmaceutical, and Teva, holding about 42% of the market shares.
| Report Metric | Details |
| Report Name | Platinum based Cancer Drug Market |
| Accounted market size in 2022 | US$ 1541.9 in million |
| Forecasted market size in 2029 | US$ 1862.2 million |
| CAGR | 2.7% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Sanofi, Hengrui Medicine, ASK Pharma, Yi Bai Pharmaceutical, Qilu Pharmaceutical, Teva, Pfizer, Dr Reddy's Laboratories, Mylan, Sun Pharma, Novartis, Debiopharm, Accord Healthcare, SK Chemicals |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
